Elevated Plasma Matrix Metalloproteinase 8 Associates With Sputum Culture Positivity in Pulmonary Tuberculosis . (1st May 2022)

• Record Type: Journal Article
• Authors: Walker, N F; Karim, F; Moosa, M Y S; Moodley, S; Mazibuko, M; Khan, K; Sterling, T R; van der Heijden, Y F; Grant, A D; Elkington, P T; Pym, A; Leslie, A
• Is Part Of: Journal of infectious diseases. Volume 226:Number 5(2022)
• Page Start: 928
• Page End: 932
• Publication Date: 2022-05-01
• Subjects: Tuberculosis -- HIV -- matrix metalloproteinase -- procollagen III N-terminal propeptide -- diagnosis -- immunopathology; Communicable diseases -- Periodicals; Diseases -- Causes and theories of causation -- Periodicals; Medicine -- Periodicals; Communicable Diseases -- Periodicals; Electronic journals; 616.9
• DOI: 10.1093/infdis/jiac160
• Languages: English
• ISSNs: 0022-1899

Abstract

Abstract: Current methods for tuberculosis treatment monitoring are suboptimal. We evaluated plasma matrix metalloproteinase (MMP) and procollagen III N-terminal propeptide concentrations before and during tuberculosis treatment as biomarkers. Plasma MMP-1, MMP-8, and MMP-10 concentrations significantly decreased during treatment. Plasma MMP-8 was increased in sputum Mycobacterium tuberculosis culture–positive relative to culture-negative participants, before (median, 4993 pg/mL [interquartile range, 2542–9188] vs 698 [218–4060] pg/mL, respectively; P = .004) and after (3650 [1214–3888] vs 720 [551–1321] pg/mL; P = .008) 6 months of tuberculosis treatment. Consequently, plasma MMP-8 is a potential biomarker to enhance tuberculosis treatment monitoring and screen for possible culture positivity. Abstract : In this cohort study, plasma matrix metalloproteinase 8 was increased in sputum culture–positive participants at tuberculosis diagnosis and after 6 months of tuberculosis treatment, demonstrating its potential as a biomarker of sputum culture positivity, to enhance tuberculosis treatment monitoring.